CDXS 📈 Codexis - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1920051067
CDXS: Enzymes, Proteins, Biocatalysts, Screening, Engineering Services
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. Web URL: https://www.codexis.com
Additional Sources for CDXS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CDXS Stock Overview
| Market Cap in USD | 457m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2010-04-22 |
CDXS Stock Ratings
| Growth 5y | -64.1% |
| Fundamental | -62.4% |
| Dividend | - |
| Rel. Strength Industry | 1459 |
| Analysts | 4.29/5 |
| Fair Price Momentum | 4.88 USD |
| Fair Price DCF | - |
CDXS Dividends
No Dividends PaidCDXS Growth Ratios
| Growth Correlation 3m | 93% |
| Growth Correlation 12m | 39.1% |
| Growth Correlation 5y | -75.5% |
| CAGR 5y | -20.76% |
| CAGR/Mean DD 5y | -0.35 |
| Sharpe Ratio 12m | 0.97 |
| Alpha | 24.78 |
| Beta | 1.86 |
| Volatility | 82.47% |
| Current Volume | 3250.1k |
| Average Volume 20d | 875.4k |
What is the price of CDXS stocks?
As of December 21, 2024, the stock is trading at USD 5.28 with a total of 3,250,119 shares traded.
Over the past week, the price has changed by -4.52%, over one month by +21.94%, over three months by +70.32% and over the past year by +80.20%.
As of December 21, 2024, the stock is trading at USD 5.28 with a total of 3,250,119 shares traded.
Over the past week, the price has changed by -4.52%, over one month by +21.94%, over three months by +70.32% and over the past year by +80.20%.
Is Codexis a good stock to buy?
No, based on ValueRay Fundamental Analyses, Codexis (NASDAQ:CDXS) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -62.40 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDXS as of December 2024 is 4.88. This means that CDXS is currently overvalued and has a potential downside of -7.58%.
No, based on ValueRay Fundamental Analyses, Codexis (NASDAQ:CDXS) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -62.40 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDXS as of December 2024 is 4.88. This means that CDXS is currently overvalued and has a potential downside of -7.58%.
Is CDXS a buy, sell or hold?
Codexis has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy CDXS.
Codexis has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy CDXS.
- Strong Buy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for CDXS stock price target?
According to ValueRays Forecast Model, CDXS Codexis will be worth about 5.6 in December 2025. The stock is currently trading at 5.28. This means that the stock has a potential upside of +6.06%.
According to ValueRays Forecast Model, CDXS Codexis will be worth about 5.6 in December 2025. The stock is currently trading at 5.28. This means that the stock has a potential upside of +6.06%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7.2 | 35.8% |
| Analysts Target Price | 7.7 | 46% |
| ValueRay Target Price | 5.6 | 6.1% |